MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Vivos Therapeutics Cost of Revenue 2011-2026 | VVOS
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Vivos Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.01 M | 5.53 M | 200 K | 400 K | 100 K | 2.74 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.01 M | 100 K | 2.5 M |
Quarterly Cost of Revenue Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.85 M | 1.71 M | 1.51 M | - | 1.53 M | 1.4 M | 1.48 M | - | 1.55 M | 1.3 M | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 709 K | 545 K | 780 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.85 M | 100 K | 892 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M |  USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Xtant Medical Holdings
XTNT
|
49.1 M | $ 0.55 | -2.31 % | $ 73.5 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.19 B | $ 88.57 | -0.65 % | $ 18 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 10.93 | -5.12 % | $ 1.64 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.4 | 4.21 % | $ 41.1 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 34.58 | -5.62 % | $ 1.07 B | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.59 | -1.18 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.15 | -5.29 % | $ 3.36 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 79.34 | -3.36 % | $ 46.4 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.2 | -1.84 % | $ 1.51 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.52 | -5.08 % | $ 364 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
161 K | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
14 M | $ 0.7 | 2.32 % | $ 29.3 M | USA |
 |
Penumbra
PEN
|
461 M | $ 335.1 | -0.39 % | $ 13 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 50.13 | -0.63 % | $ 1.47 B | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
Surgalign Holdings
SRGA
|
41.7 M | - | -32.98 % | $ 1.68 M | USA |
 |
STRATA Skin Sciences
SSKN
|
14.4 M | - | - | $ 6.6 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
AVITA Medical
RCEL
|
12.8 M | $ 3.82 | -1.04 % | $ 106 M |  Australia |
 |
AxoGen
AXGN
|
57.9 M | $ 31.28 | -3.01 % | $ 1.44 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 8.97 | -1.75 % | $ 321 M | USA |